Aperion begins trial of Z-Lig ACL graft
This article was originally published in Clinica
Executive Summary
Aperion Biologics has started a clinical trial of its Z-Lig anterior cruciate ligament (ACL) reconstruction device for the treatment of ligament injuries of the knee. The device is an immunochemically-modified porcine tissue-based implant, and is the only known biological alternative to human tissue for ACL replacement in clinical evaluation, San Antonio, Texas-based Aperion claims. The implant maintains a mechanically stable scaffold, and can become populated and remodelled with the patient's own cells. Results will be used to support regulatory approvals and clinical acceptance of Z-Lig in markets outside the US. Aperion has already completed a two-year clinical study on Z-Lig in the US, in which the grafts demonstrated safety and feasibility.